SITC Archive Library

The Society for Immunotherapy of Cancer (SITC) hosted the “The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations” program during the 36th Annual Meeting & Pre-Conference Programs on November 10, 2021. Available here are the presentation slides and video from "Session I: Immunity Beyond T cells," as permitted by presenters.

Program Summary

It has been a decade since the first approval of an immune checkpoint inhibitor. In the ten years since, the field of cancer immunotherapy has seen unprecedented growth. In order to further improve patient outcomes, cancer immunotherapy approaches are constantly evolving. This program discussed three key areas for the future of cancer immunotherapy: immunity beyond T cells, the application of CAR T therapy in solid tumors, and novel immunotherapy combinations. Addressing these key areas will help the next ten years of immunotherapy be as successful as the last.

Program Organizers

• Kald Abdallah, MD, PhD – Bristol Myers Squibb
• Mary Margaret Huizinga, MD, MPH, FACP
• Francesco M. Marincola, MD – Kite, A Gilead Company
• Giovanni Melillo, MD – AstraZeneca
• Zhen Su, MD, PhD – Marengo Therapeutics

To view the entire program schedule (including presenter permission to post) please click here.